Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets
(2014) In Cancer and Metastasis Reviews 33(1). p.345-351- Abstract
- Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising... (More)
- Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers. (Less)
Please use this url to cite or link to this publication:
https://lup.lub.lu.se/record/4495847
- author
- Capdevila, J.
; Meeker, A.
; Garcia-Carbonero, R.
; Pietras, Kristian
LU
; Astudillo, A. ; Casanovas, O. and Scarpa, A.
- organization
- publishing date
- 2014
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Neuroendocrine tumors, Biomarker, Chromogranin A
- in
- Cancer and Metastasis Reviews
- volume
- 33
- issue
- 1
- pages
- 345 - 351
- publisher
- Springer
- external identifiers
-
- wos:000334423700020
- scopus:84899941260
- pmid:24375391
- ISSN
- 0167-7659
- DOI
- 10.1007/s10555-013-9468-y
- language
- English
- LU publication?
- yes
- id
- fcd303f4-1fba-43b9-bcc1-fc6e0f91edb5 (old id 4495847)
- date added to LUP
- 2016-04-01 10:34:39
- date last changed
- 2022-02-02 19:09:16
@article{fcd303f4-1fba-43b9-bcc1-fc6e0f91edb5, abstract = {{Neuroendocrine tumors (NETs) represent a heterogeneous group of diseases with varied natural history and prognosis depending upon the organ of origin and grade of aggressiveness. The most widely used biomarker to determine disease burden and monitor response to treatment is chromogranin A (CgA), but it is far from being the optimal predictive and prognostic biomarker in NETs. Biological understanding and derived treatment options for NETs have changed markedly in recent years. Over the last decade, the genomic landscape of these tumors has been extensively investigated. This has resulted in the discovery of mutations and expression anomalies in genes and pathways such as the PI3K/Akt/mTOR, DAXX/ATRX, and MEN1, which are promising predictive and prognostic biomarkers and future candidates for targeted therapies. Additionally, the study of tumor stroma and environment are one of the most promising fields for discovery of potential new targets and biomarkers.}}, author = {{Capdevila, J. and Meeker, A. and Garcia-Carbonero, R. and Pietras, Kristian and Astudillo, A. and Casanovas, O. and Scarpa, A.}}, issn = {{0167-7659}}, keywords = {{Neuroendocrine tumors; Biomarker; Chromogranin A}}, language = {{eng}}, number = {{1}}, pages = {{345--351}}, publisher = {{Springer}}, series = {{Cancer and Metastasis Reviews}}, title = {{Molecular biology of neuroendocrine tumors: from pathways to biomarkers and targets}}, url = {{http://dx.doi.org/10.1007/s10555-013-9468-y}}, doi = {{10.1007/s10555-013-9468-y}}, volume = {{33}}, year = {{2014}}, }